All Stemell premium umbilical-cord-derived products are minimally manipulated and highly purified. Our proprietary process yields the greatest amount of viable product.

Stemell products are registered with the FDA, Tissue Bank, NIH and FWA. We operate out of a Certified Class 100 Clean Room and follow GMP, GLP and GTP good manufacturing practices. All Stemell products are tested for microbial and viral pathogens.

StemL UCB-Plus™

Umbilical Cord Blood Cell Allograft Product (Highly Purified)


  • 1 cc (5 million)
  • 2 cc (10 million)
  • 2 cc & 5 cc (30 million)*
*5 cc manufactured for special orders only

Is an umbilical cord blood allograft which is flexible and more immature as compared to bone marrow derived hematopoietic and mesenchymal stem cells. They have the capacity to multiply quickly and work with the body’s cellular system to repair damage.


  • Rich source of T-Cells and B-Cells
  • Rich source of hematopoietic, mesenchymal and endothelial stem cells
  • Homologous use only
  • Allogeneic umbilical cord blood stem cell
  • Code of federal regulations: HCT/Ps 21 CFR 1271.3(c)
  • 5 x 106 cell per 1 cc
  • Cord blood procured from live, healthy donors during childbirth

StemL UCT™

Wharton’s Jelly Umbilical Cord Tissue Driven Allograft “Acellular” Product


  • .5 cc
  • 1 cc
  • 2 cc

Is an acellular wharton’s jelly umbilical cord tissue driven allograft. This product contains no live cells, however it is a rich source of protein, cytokines and growth factors.


  • Homologous use only
  • Allogeneic umbilical cord tissue acellular product
  • Code of federal regulations: HCT/Ps 21 CFR 1271.3(c)
  • Procured from live, healthy donors during childbirth

StemL UCT-Plus™

Wharton’s Jelly Umbilical Cord Tissue Driven Allograft “Cellular” Product


  • .5 cc (750 thousand)
  • 1 cc (1.5 million)
  • 2 cc (3 million)

Is a wharton’s jelly umbilical cord tissue driven allograft which yields the highest amount of clinically utilizable young mesenchymal stem cells making them valuable for a variety of applications in regenerative medicine.

  • Rich source of mesenchymal stromal cells
  • Homologous use only
  • Allogeneic umbilical cord tissue stem cell
  • Code of federal regulations: HCT/Ps 21 CFR 1271.3(c)
  • Procured from live, healthy donors during childbirth

StemL X-Plus™

Highly Purified Umbilical Cord Driven Exosome Product


  • 2 cc (225 billion)
  • 4 cc (625 billion)

StemL X-Plus™ is a highly purified exosome product derived from concentrated umbilcial cord blood platelet rich Plasma (PRP). These nano-sized vesicles facilitate a range of important cellular functions by improving the mechanism of communication among cells.

  • Homologous use only
  • Cell-free
  • Rich source of protien, cytokines and growth factors
  • Culture-free, serum-free, bovine-free and xeno-free
  • Code of federal regulations: HCT/Ps 21 CFR 1271.3(c)
  • Procured from live, healthy donors during childbirth

How to Order

Initial registration is required to place your first order. Visit our registration and ordering page.


For Medical Professional Viewing Only


Stemell, Inc. does not claim that therapy using StemL products cures or prevents any condition, disease or injury. All statements and opinions provided are for educational and informational purposes only, and we do not diagnose or provide medical or legal advice.

Individuals interested in any cellular or cell-free regenerative medicine therapy are urged to review all pertinent information and do their own research and due diligence before choosing to participate in any therapies. Please consult with your physician for further information and be sure to discuss any potential risks.

Please understand that Stemell, Inc. is a supplier only. Stemell, Inc. is not a sponsor, and Stemell, Inc. is not claiming to cure or treat any disorder or condition.

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.

The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.

This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.

“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else. If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.

Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.